Physician profile
Nathan E Schrock
NPI 1679573372
$27,587.85
in general payments reported to CMS, 2019-2025
65 companies · $5,353 in 2025
The $5,353 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,705 · 2020: $2,252 · 2021: $3,426 · 2022: $3,674 · 2023: $4,446 · 2024: $4,731 · 2025: $5,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,126.04 |
| Education | $403.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,342.83 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $2,166.11 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| Celgene Corporation | $1,651.02 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Novartis Pharmaceuticals Corporation | $1,629.80 | 2019-2025 | Kisqali |
| Seagen INC. | $1,544.35 | 2019-2025 | Tukysa, Adcetris |
| Genentech USA, INC. | $1,485.79 | 2019-2025 | Phesgo, Perjeta, Tecentriq |
| Janssen Biotech, INC. | $1,269.72 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Pfizer INC. | $1,047.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,019.92 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $1,008.65 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Glaxosmithkline, LLC. | $718.58 | 2020-2025 | Ojjaara, Jemperli, Shingrix |
| Daiichi Sankyo INC. | $611.17 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $599.07 | 2019-2025 | |
| Eisai INC. | $577.94 | 2019-2025 | |
| Amgen INC. | $564.17 | 2019-2023 | Kyprolis, Lumakras, Xgeva |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $535.81 | 2019-2025 | Padcev, Vyloy, Xospata |
| Genzyme Corporation | $517.69 | 2019-2025 | |
| Gilead Sciences, INC. | $501.54 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $474.73 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Abbvie INC. | $473.70 | 2020-2025 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $425.12 | 2019-2025 | Libtayo |
| Lilly USA, LLC | $396.10 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $393.06 | 2021-2025 | Fotivda |
| Exelixis INC. | $384.23 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $368.50 | 2020-2025 | Brukinsa |
| Emd Serono, INC. | $298.34 | 2020-2025 | Bavencio |
| Array Biopharma INC | $278.29 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $242.03 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $239.68 | 2021-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $237.85 | 2019-2024 | Onivyde |
| Kite Pharma, INC. | $206.16 | 2020-2023 | |
| Pharmacosmos Therapeutics INC. | $195.26 | 2020-2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.12 | 2019-2025 | Gilotrif |
| Taiho Oncology, INC. | $150.79 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $144.36 | 2021-2025 | |
| Caris Mpi, INC. | $135.25 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $127.47 | 2022-2025 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $127.18 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Tempus Ai, INC | $97.59 | 2025 | Xt Cdx |
| Acceleron Pharma, INC. | $97.44 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $95.28 | 2022-2025 | |
| Mirati Therapeutics, INC. | $95.00 | 2023-2024 | Krazati |
| Amag Pharmaceuticals, INC. | $73.23 | 2019-2022 | |
| Morphosys, US INC. | $66.11 | 2022-2023 | Monjuvi |
| Epizyme, INC. | $65.17 | 2021-2022 | |
| Iovance Biotherapeutics, INC. | $61.21 | 2025 | Amtagvi |
| Deciphera Pharmaceuticals INC. | $57.97 | 2024-2025 | Qinlock, Romvimza |
| Sobi, INC | $57.47 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $57.29 | 2023-2025 | Xpovio |
| Genentech, INC. | $47.95 | 2020 | |
| Stemline Therapeutics INC. | $44.75 | 2023-2025 | Orserdu |
| Blueprint Medicines Corporation | $42.09 | 2023-2024 | Ayvakit |
| Apellis Pharmaceuticals, INC. | $39.12 | 2023-2024 | Empaveli |
| Agios Pharmaceuticals, INC. | $35.79 | 2024-2025 | Pyrukynd |
| Verastem, INC. | $31.52 | 2019 | |
| Dova Pharmaceuticals | $24.26 | 2020-2021 | |
| Tg Therapeutics, INC. | $23.57 | 2021 | |
| Tesaro, INC. | $22.59 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.17 | 2024 | Amvuttra |
| Pharmaessentia USA Corporation | $20.03 | 2023 | Besremi |
| Foundation Medicine, INC. | $17.86 | 2020 | |
| Nuvation Bio INC. | $16.41 | 2025 | Ibtrozi |
| Sirtex Medical INC | $15.00 | 2023 | Sir-Spheres Microspheres |
| Aadi Bioscience, INC. | $14.02 | 2023 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Schrock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.